Last updated: February 15, 2026
Product Overview
NDC 78206-0174 corresponds to Kymriah (tisagenlecleucel), a chimeric antigen receptor T-cell (CAR-T) therapy developed by Novartis for the treatment of certain blood cancers. It is FDA-approved for:
- Acute lymphoblastic leukemia (ALL) in patients up to 25 years old.
- Diffuse large B-cell lymphoma (DLBCL) in adults who have failed two or more prior therapies.
Market Size and Demographics
- Patient Population: The U.S. pediatric and young adult ALL population is approximately 600-700 annual cases, representing a niche but growing market. For DLBCL, approximately 20,000 new cases occur annually in the U.S.
- Market Penetration: As of 2023, CAR-T therapies like Kymriah hold about 20% penetration in eligible indications, with growth expected as awareness and infrastructure expand.
- Competitive Landscape: Yescarta (Gilead), Breyanzi (Bristol-Myers Squibb), and Tecartus (Gilead) compete in the CAR-T space; Kymriah has established a strong position, especially in pediatric ALL.
Pricing Strategy and Revenue Trends
- List Price: Kymriah’s wholesale acquisition cost (WAC) was approximately $475,000 per treatment in 2023, corresponding to the one-time administration.
- Pricing Components:
- The price primarily covers manufacturing, personalized cell therapy, and clinical support.
- Reimbursement varies among payers but typically includes exclusive agreements.
- Revenue Trends:
- Novartis reported revenues of approximately $269 million from Kymriah in 2022.
- Year-over-year growth reflects increased patient access and expanded indications.
Market Dynamics
- Pricing Pressures: Payers scrutinize high-cost therapies; price negotiations and performance-based agreements are common.
- Access Expansion: Efforts to broaden infrastructure for CAR-T delivery, including hospital preparedness and specialist training, influence market penetration.
- Regulatory Updates: FDA approvals in additional indications or age groups could expand market size or justify price adjustments.
Price Projections (Next 5 Years)
| Year |
Estimated Average Price |
Rationale |
| 2024 |
$475,000 |
Current wholesale price maintained; inflation-adjusted. |
| 2025 |
$470,000 |
Slight discounts via payor negotiations. |
| 2026 |
$460,000 |
Market saturation begins; competitive pressures increase. |
| 2027 |
$440,000 |
Further price realignment with alternative therapies. |
| 2028 |
$430,000 |
Mature market pressures; focus on value-based contracting. |
Factors Influencing Price Trends
- Manufacturing Costs: Reduction in production costs from process innovations could lower prices.
- Regulatory Changes: Approvals for additional indications and broader patient access may influence revenue potential and pricing.
- Competitive Strategies: Biosimilars or alternative therapies could exert downward pressure.
- Policy and Reimbursement: Value-based pricing models and government negotiations will shape final reimbursement levels.
Conclusion
Kymriah’s market remains specialized, with pricing reflecting personalized manufacturing and limited patient volumes. While the current price is approximately $475,000 per treatment, market forces, payer negotiations, and operational efficiencies could gradually lower prices in the medium term.
Key Takeaways
- NDC 78206-0174 (Kymriah) is a leading CAR-T therapy with a price around $475,000.
- The market size is constrained by specific indications but expanding through new approvals.
- Revenue growth relies on increased adoption, infrastructure, and indication expansion.
- Price projections suggest stable pricing with gradual declines due to competitive pressure and policy reforms.
FAQs
1. What factors could significantly alter Kymriah’s price?
Regulatory changes, expansion of indications, competitive therapies, and shifts toward value-based reimbursement models.
2. How does Kymriah compare to its competitors in pricing?
Kymriah’s price is comparable to Yescarta and Breyanzi, generally within the $400,000-$500,000 range, but varies based on payer negotiations and indication.
3. What is the outlook for expanding Kymriah’s indications?
Approval for additional hematologic cancers or adult indications could increase market size, potentially stabilizing or elevating prices.
4. How do reimbursement policies impact Kymriah’s market access?
Payers increasingly seek outcome-based agreements, which can influence effective pricing and patient access levels.
5. What innovations might reduce manufacturing costs?
Automation, process optimization, and scalable manufacturing could decrease costs, enabling price reductions or margin improvements.
References
[1] Novartis Reports 2022 Financial Results, https://www.novartis.com/investors/financial-results
[2] FDA Approvals and Indications, https://www.fda.gov
[3] Market Size and Trends, IQVIA Institute Reports, 2023
[4] Industry Pricing Reports, BioPharma Dive, 2023
